{"title":"具有竞争风险的治愈率数据的缺陷回归模型。","authors":"K Silpa, E P Sreedevi, P G Sankaran","doi":"10.1080/10543406.2024.2424838","DOIUrl":null,"url":null,"abstract":"<p><p>In this paper, we propose a novel method for the analysis of cure rate data with competing risks using defective distributions. We develop two defective regression models for the analysis of competing risk data subjected to random right censoring. The proposed models enable us to estimate the cure fraction directly from the model. Simultaneously, we also estimate the regression parameters corresponding to each cause of failure using the method of maximum likelihood. We conduct a simulation study to evaluate the finite sample performance of the proposed estimators. The practical usefulness of the procedures is illustrated using two real-life data sets.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-17"},"PeriodicalIF":1.2000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Defective regression models for cure rate data with competing risks.\",\"authors\":\"K Silpa, E P Sreedevi, P G Sankaran\",\"doi\":\"10.1080/10543406.2024.2424838\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this paper, we propose a novel method for the analysis of cure rate data with competing risks using defective distributions. We develop two defective regression models for the analysis of competing risk data subjected to random right censoring. The proposed models enable us to estimate the cure fraction directly from the model. Simultaneously, we also estimate the regression parameters corresponding to each cause of failure using the method of maximum likelihood. We conduct a simulation study to evaluate the finite sample performance of the proposed estimators. The practical usefulness of the procedures is illustrated using two real-life data sets.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2024.2424838\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2024.2424838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Defective regression models for cure rate data with competing risks.
In this paper, we propose a novel method for the analysis of cure rate data with competing risks using defective distributions. We develop two defective regression models for the analysis of competing risk data subjected to random right censoring. The proposed models enable us to estimate the cure fraction directly from the model. Simultaneously, we also estimate the regression parameters corresponding to each cause of failure using the method of maximum likelihood. We conduct a simulation study to evaluate the finite sample performance of the proposed estimators. The practical usefulness of the procedures is illustrated using two real-life data sets.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.